Drugs / AGEN2373
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07193862 | Dec 2025 → Apr 2028 expected | colorectal cancer | Northwell Health | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04121676 | Sep 2019 → Feb 2024 | cancer of unknown primary site | Agenus Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06782932 | May 2025 → Dec 2028 expected | pancreatic adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-06-05 | Agenus Inc. | Results Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO agenusbio.com ↗
AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily pre-treated patients with solid tumors. |
| 2021-05-20 | Agenus Inc. | Results Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts agenusbio.com ↗
new Phase 1 clinical data for AGEN2373, a CD137 agonist antibody |
| 2020-11-09 | Agenus Inc. | Results Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020 agenusbio.com ↗
AGEN2373 , an anti- CD137 agonist monotherapy , shows clinical benefit without liver toxicity |
| 2020-08-06 | Agenus Inc. | Results Agenus Provides R&D Update & Second Quarter Financial Report agenusbio.com ↗
AGEN2373 achieves durable SDs in early Ph1 |
| 2019-08-08 | Agenus Inc. | Regulatory Agenus Milestone Triggers $7.5M Payment agenusbio.com ↗
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, announced today that the FDA has accepted the company's IND filing for AGEN2373, a milestone in its partnership with Gilead Sciences, Inc. |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-05 | Agenus Inc. | Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO agenusbio.com ↗ |
| 2022-04-05 | Agenus Inc. | Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead agenusbio.com ↗ |
| 2021-06-04 | Agenus Inc. | Agenus’ Presentations at ASCO 2021 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373 agenusbio.com ↗ |
| 2021-05-20 | Agenus Inc. | Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts agenusbio.com ↗ |
| 2020-11-09 | Agenus Inc. | Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020 agenusbio.com ↗ |
| 2020-08-06 | Agenus Inc. | Agenus Provides R&D Update & Second Quarter Financial Report agenusbio.com ↗ |
| 2019-08-08 | Agenus Inc. | Agenus Milestone Triggers $7.5M Payment agenusbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGEN2373 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07193862 ↗ |
| Route | Intravenous | “3+3 Dose escalation of AGEN2373 administered by IV.” NCT04121676 ↗ |